Hemangiosarcoma in Dogs: Symptoms, Treatment Options & Prognosis Guide

Hemangiosarcoma is an aggressive, malignant cancer that originates in the endothelial cells — the cells that line blood vessels and the lymphatic system. It is one of the most devastating diagnoses a dog owner can face. This cancer causes tumors to form wherever blood vessels exist, but most commonly targets the spleen, heart, liver, and skin. According to the Merck Veterinary Manual, hemangiosarcoma accounts for approximately 45–50% of all canine splenic masses and roughly 5–7% of all cancers diagnosed in dogs. The disease progresses rapidly, and because internal tumors often remain silent until they rupture and cause life-threatening internal bleeding, many dogs are diagnosed at an advanced stage. Understanding the warning signs, diagnostic process, and realistic treatment outcomes is essential for any dog owner — particularly those with breeds at elevated risk.

What Is Hemangiosarcoma in Dogs?

Hemangiosarcoma (HSA) is a cancer of vascular endothelial cells — the specialized cells forming the inner lining of every blood vessel in your dog's body. When these cells become malignant, they proliferate uncontrollably, forming tumors that are inherently fragile and blood-filled. These tumors can develop anywhere vascular tissue exists, but they follow predictable patterns:

• Splenic hemangiosarcoma: The most common form, representing roughly 80% of cases. The spleen acts as a blood reservoir, making it a prime site for vascular tumors.
• Cardiac (heart) hemangiosarcoma: Typically forms on the right atrium or auricle of the heart. Accounts for approximately 10–15% of cases and is the most common cardiac tumor in dogs.
• Cutaneous (skin) hemangiosarcoma: Appears as dark red or purple raised masses on the skin. This form has the best prognosis when caught early and surgically removed.
• Hepatic (liver) and osseous (bone) hemangiosarcoma: Less common but equally aggressive presentations.

A critical feature of hemangiosarcoma is its tendency to metastasize (spread) early and widely. By the time a splenic tumor is detected, microscopic metastasis to the liver, lungs, omentum, or other organs is often already present — even when imaging appears clear. The American Kennel Club notes that approximately 80% of dogs with splenic hemangiosarcoma have metastasis at the time of diagnosis, which fundamentally shapes treatment decisions and prognosis.

Recognizing the Symptoms: Early Warning Signs vs. Advanced Disease

Hemangiosarcoma is notoriously difficult to detect early. Internal tumors grow silently, and clinical signs often don't appear until the tumor ruptures or becomes large enough to compress surrounding organs. The symptoms vary significantly depending on tumor location and stage.

Breed Predisposition and Risk Factors

While hemangiosarcoma can affect any dog, certain breeds carry dramatically elevated risk. Research published in the Journal of Veterinary Internal Medicine has identified strong genetic predispositions, and ongoing research by the AKC Canine Health Foundation continues to investigate hereditary factors.

If you own a breed in the high-risk category, discuss screening protocols with your veterinarian during annual wellness visits. While no standardized screening test exists for early hemangiosarcoma detection, baseline bloodwork and abdominal ultrasound in senior dogs of high-risk breeds can sometimes catch splenic masses before they rupture.

How Veterinarians Diagnose Hemangiosarcoma

Diagnosis follows a staged approach, beginning with emergency stabilization (if the dog presents in crisis) and progressing through imaging, laboratory analysis, and ultimately histopathology for confirmation. Here is what to expect at each step:

Step 1: Initial Assessment and Stabilization

If your dog presents with collapse or signs of internal bleeding, the veterinarian will prioritize stabilization before diagnostics. This typically includes IV fluid therapy, oxygen supplementation, and potentially a blood transfusion. Cost: $200–$800 for emergency stabilization alone.

Step 2: Diagnostic Imaging

Step 3: Laboratory Work

Your veterinarian will run a comprehensive blood panel including:

• Complete Blood Count (CBC): Often reveals anemia (low red blood cells), thrombocytopenia (low platelets), and the presence of schistocytes (fragmented red blood cells) — a hallmark finding in HSA
• Serum Biochemistry Panel: Assesses liver and kidney function; may show elevated liver enzymes if hepatic involvement is present
• Coagulation Profile (PT/aPTT, D-dimers): Evaluates clotting function; DIC (disseminated intravascular coagulation) is a common and dangerous complication of HSA
• Cardiac Biomarkers (cTnI, NT-proBNP): May support cardiac HSA suspicion, though not diagnostic alone

Lab work typically costs $150–$350 depending on the panel breadth.

Step 4: Definitive Diagnosis via Histopathology

The only way to confirm hemangiosarcoma is through tissue analysis. This occurs either through:

• Surgical biopsy/splenectomy: The spleen (or mass) is removed and submitted to a veterinary pathologist. Results typically return in 5–10 business days.
• Fine-needle aspirate (FNA): Less reliable for HSA because these tumors are blood-filled and aspirates often yield only blood, not diagnostic cells. Accuracy is approximately 50–60%.
• Punch or excisional biopsy (cutaneous form): Skin lesions are biopsied directly; this form is the easiest to definitively diagnose.

Histopathology costs: $150–$350 for tissue submission and pathologist review.

Treatment Options and Outcomes

Treatment for hemangiosarcoma depends heavily on tumor location, stage at diagnosis, your dog's overall health, and your goals of care. Below is a comparison of available approaches:

Chemotherapy Details: What to Expect

Doxorubicin (Adriamycin) is the most commonly used chemotherapy agent for canine hemangiosarcoma. The standard protocol involves:

• Dose: 30 mg/m² IV every 21 days for 4–6 treatments (your veterinary oncologist will calculate exact dosing based on body surface area)
• Side effects: Most dogs tolerate doxorubicin reasonably well. Approximately 20–25% experience gastrointestinal upset (vomiting, diarrhea, decreased appetite) 3–5 days post-treatment. Cardiotoxicity (heart damage) is a risk with cumulative doses, which is why echocardiograms are performed before starting treatment.
• Hair loss: Unlike humans, most dogs do not lose their coat. Whisker loss and thinning of fur in continuously growing breeds (Poodles, Shih Tzus) may occur.
• Blood count monitoring: CBC is checked 7 days after each dose to monitor for neutropenia (low white blood cells). If counts drop dangerously low, dose reduction or delay is implemented.

Always consult your veterinarian and ideally a board-certified veterinary oncologist to determine the best treatment plan for your dog's specific situation.

Prognosis and Life Expectancy by Stage

Honest prognostic information is essential for making informed decisions. Hemangiosarcoma carries a guarded to poor prognosis in most presentations, though outcomes vary meaningfully by tumor location and treatment intensity.

It is important to understand that median survival means half of dogs live longer than this timeframe and half live shorter. Individual outcomes are influenced by tumor biology, your dog's immune response, treatment complications, and factors that remain poorly understood. Some dogs with splenic HSA treated with surgery and chemotherapy do survive beyond 12 months, though this represents a minority.

Treatment Costs: Financial Planning for Hemangiosarcoma

Hemangiosarcoma treatment represents one of the more expensive cancer diagnoses due to the combination of emergency care, surgery, oncology consultations, and chemotherapy. Here is a realistic cost breakdown to help you plan:

If your dog has pet insurance with cancer coverage, reimbursements can significantly offset these costs — but only if the policy was in place before diagnosis. Pre-existing condition exclusions are universal across pet insurance providers. Review your policy's annual and lifetime maximums; many plans cap at $5,000–$15,000 per year for illness claims.

Home Care and Daily Management

Whether your dog is undergoing active treatment or receiving palliative care, daily management at home plays a crucial role in quality of life.

Post-Surgical Recovery (First 2–4 Weeks)

• Activity restriction: Leash-only walks for bathroom breaks; no running, jumping, or rough play for 10–14 days minimum. Use a harness instead of a collar to avoid abdominal pressure.
• Incision monitoring: Check the surgical site twice daily for redness, swelling, discharge, or opening. An e-collar (cone) is essential to prevent licking.
• Pain management: Administer prescribed pain medications (typically carprofen, gabapentin, or tramadol) on schedule — don't wait for visible pain signs, as dogs mask discomfort.
• Feeding: Offer small, frequent meals of easily digestible food (boiled chicken and rice, or your vet's recommended recovery diet) for the first 3–5 days, then transition back to regular diet.

Ongoing Care During Chemotherapy

• Hygiene precautions: For 48–72 hours after each chemotherapy dose, your dog's urine, feces, and vomit may contain trace chemotherapy metabolites. Wear disposable gloves when cleaning up accidents. Pregnant household members should avoid handling chemotherapy waste.
• Appetite support: Chemotherapy-related nausea may cause appetite drops. Your veterinarian may prescribe maropitant (Cerenia) or mirtazapine as an appetite stimulant. Warming food slightly or adding low-sodium broth can encourage eating.
• Blood count awareness: The nadir (lowest white blood cell count) typically occurs 7–10 days post-treatment. During this window, avoid dog parks, boarding facilities, and other high-exposure environments to reduce infection risk.
• Monitoring for recurrence: Watch for the same symptoms that prompted initial diagnosis — lethargy, pale gums, abdominal swelling, exercise intolerance — and report any recurrence to your oncologist promptly.

Palliative and Hospice Care

If you choose comfort-focused care without aggressive treatment, or if your dog has progressed beyond treatment options, focus on:

• Maintaining a consistent daily routine to reduce stress
• Providing soft, supportive bedding (orthopedic beds reduce pressure on a distended abdomen)
• Keeping your dog comfortable with prescribed pain medications — never use human NSAIDs (ibuprofen, naproxen) which are toxic to dogs
• Monitoring quality of life using a validated scale such as the HHHHHMM Quality of Life Scale (Hurt, Hunger, Hydration, Hygiene, Happiness, Mobility, More good days than bad)
• Discussing humane euthanasia timing with your veterinarian — this is often the kindest final gift when pain becomes unmanageable or your dog's bad days consistently outnumber good ones

Prevention: What We Know and What We Don't

There is currently no proven method to prevent hemangiosarcoma in dogs. Unlike some cancers linked to specific environmental exposures or hormonal factors, HSA appears driven primarily by genetic predisposition and age-related cellular changes. However, several strategies may reduce risk or improve early detection:

• Responsible breeding: Reputable breeders of high-risk breeds should track cancer incidence in their lines. The AKC Canine Health Foundation funds ongoing hemangiosarcoma research, including genetic studies in Golden Retrievers and German Shepherds. When selecting a puppy, ask breeders about cancer history in their breeding dogs' pedigrees.
• Senior wellness screening: For high-risk breeds, annual abdominal ultrasound beginning at age 7–8 may detect splenic masses before they rupture. While this doesn't prevent HSA, earlier detection allows planned (rather than emergency) surgery, which carries lower complication rates and costs.
• Spay/neuter timing: Some research suggests early spaying (before first heat) may modestly increase hemangiosarcoma risk in certain breeds, though the evidence is mixed and must be weighed against the significant benefits of spaying (pyometra prevention, mammary cancer reduction). Discuss optimal timing with your veterinarian based on breed and individual risk factors.
• Sun protection for cutaneous HSA: Light-skinned, thin-coated breeds (Whippets, American Staffordshire Terriers, Dalmatians) may benefit from limiting UV exposure on the belly and inner thighs. Pet-safe sunscreen (zinc oxide-free, formulated for dogs) can be applied to exposed skin during peak sun hours.

When to See the Vet: Red Flag Symptoms

Non-Emergency but Prompt Veterinary Visit Warranted:

• A new dark purple or red raised mass on the skin — schedule an appointment within 1–2 weeks
• Progressive exercise intolerance in a senior large-breed dog — especially Golden Retrievers and German Shepherds
• Unexplained weight loss with or without appetite changes
• Recurrent episodes of weakness that resolve on their own — these "mini-collapse" events often precede a major hemorrhagic crisis
• Abdominal distension noted during routine grooming or petting

Frequently Asked Questions

Is hemangiosarcoma in dogs painful?

In its early stages, hemangiosarcoma is not typically painful. The tumors grow internally and don't cause pain until they become large enough to stretch the organ capsule or press on adjacent structures. When a splenic tumor ruptures, however, the resulting internal hemorrhage causes acute distress, weakness, and abdominal pain. Cutaneous (skin) hemangiosarcoma lesions can be painful if they ulcerate or become infected. Your veterinarian can prescribe appropriate pain management for any stage of the disease.

Can hemangiosarcoma be cured?

Cutaneous hemangiosarcoma, when caught as a single superficial lesion and completely excised with clean surgical margins, can be cured in many cases. Unfortunately, internal forms (splenic, cardiac, hepatic) are rarely curable because microscopic metastasis is almost always present at diagnosis, even when imaging appears clear. Treatment for internal HSA is focused on extending life and maintaining quality of life rather than achieving a cure.

Should I have my dog's spleen removed if a mass is found but not yet diagnosed?

This is a common and difficult question. If an ultrasound reveals a splenic mass and your dog is stable, your veterinarian may recommend either monitoring with repeat ultrasound in 2–4 weeks or proceeding with a planned splenectomy. Planned (non-emergency) splenectomy carries significantly lower risk than emergency surgery on a hemorrhaging, unstable dog. Many veterinarians recommend proactive removal if the mass is large (>5 cm), growing, or if your dog is a high-risk breed — even before it causes symptoms. Discuss the risks and benefits with your veterinarian.

Are there any clinical trials for hemangiosarcoma in dogs?

Yes. Several veterinary teaching hospitals and research institutions conduct ongoing clinical trials. The University of Minnesota, Colorado State University, and the University of Pennsylvania School of Veterinary Medicine have active or recent hemangiosarcoma research programs. The AKC Canine Health Foundation maintains a clinical trial database. Participation may provide access to novel therapies at reduced cost, though eligibility criteria vary.

What is the difference between hemangiosarcoma and hemangioma?

Hemangioma is a benign (non-cancerous) vascular tumor that does not metastasize. Hemangiosarcoma is the malignant counterpart — aggressive, invasive, and prone to widespread metastasis. They can look similar on imaging, which is why histopathology (microscopic examination of the tissue by a veterinary pathologist) is essential for accurate diagnosis. Cutaneous hemangiomas are relatively common and often cured with surgical removal alone.

How can I support my dog's quality of life during treatment?

Focus on maintaining the activities your dog enjoys most — gentle walks, favorite treats, time with family. Keep a daily journal tracking appetite, energy level, pain signs, and any symptoms. This record helps your veterinary team adjust treatment and also helps you objectively assess whether your dog is having more good days than bad. Consider consulting a veterinary hospice/palliative care specialist for guidance on end-of-life decision-making.